Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • ASAM Review Course Spotlight Webinar Series 2018 (6 CME)

    Contains 24 Component(s), Medical Credits Offered Includes a Live Event on 08/21/2018 at 3:00 PM (EDT)

    Earn 6 AMA PRA Category 1 Credit(s) while attending this six-webinar series, which will offer an additional, in-depth look at some of the most popular sessions from the ASAM Review Course in Addiction Medicine 2018. Topics include; psychiatric co-morbidities, cannabis, tobacco, prevention and public health, pharmacology and toxicology, and pain and addiction.

    REVIEW COURSE ATTENDEES RECEIVE 25% OFF - 

    Use the promo code located in your syllabus when checking out to take advantage of this special deal!

    Looking to stay engaged and expand your ASAM Review Course experience? This six-webinar series will offer an additional, in-depth look at some of the most popular sessions from the ASAM Review Course in Addiction Medicine. 

    Each webinar will be an hour long, with 30-45 minutes of lecture on the topic of the week and the rest saved for audience questions. Questions have been collected in advance from participants of the 2018 Review Course and all attendees will have the opportunity to submit questions during the live webinar!

    All webinars will be recorded and available to watch for registrants unable to attend live. 

    DateTime (Eastern)
    Topic
    Tuesday, August 213:00 pm – 4:00 pmPsychiatric Co-Morbidities
    Richard Ries, MD, DFASAM
    Tuesday, August 2812:00 pm – 1:00 pmCannabis
    Carla Marienfeld, MD
    Thursday, August 3012:00 pm – 1:00 pmTobacco
    Abigail Herron, DO, FAPA, DFASAM
    Wednesday, September 512:00 pm – 1:00 pmPrevention and Public Health
    Sharon Stancliff, MD, FASAM
    Friday, September 712:00 pm – 1:00 pmPharmacology and Toxicology
    Timothy Wiegand, MD, FACMT, FAACT
    Monday, September 1012:00 pm – 1:00 pmPain and Addiction
    Edwin Salsitz, MD, DFASAM

     

    Edwin A. Salsitz

    MD, DFASAM

    Dr. Edwin A. Salsitz has been an attending physician in the Mount Sinai Beth Israel , Division of Chemical Dependency, New York City, since 1983, and is an Assistant Professor of Psychiatry at the Mount Sinai School of Medicine. He is the principal investigator of the Methadone Medical Maintenance (office-based methadone maintenance) research project. 

    Dr. Salsitz is certified by the American Board of Addiction Medicine (ABAM), as well as by the Board of Internal Medicine and Pulmonary Disease. He has published and lectures frequently on addiction medicine topics.Dr. Salsitz is a course director for ASAM sponsored buprenorphine trainings,and is a mentor in the PCSS-MAT mentoring program. He has co-chaired the ASAM Review Course, the ASAM Common Threads Course, the ASAM State of the Art course and is a reviewer for the Journal of Addiction Medicine and Drug and Alcohol Dependence. He is the chair of the ASAM REMS course on safe and effective prescribing of opioids. 

    Dr. Salsitz was the Co-chair of the ASAM CME committee and Chair of the New York Society of Addiction Medicine CME and Education committee. Dr. Salsitz is a member of the medical advisory panel, for the New York State Office of Alcohol and Substance Abuse Services.  Dr. Salsitz is the recipient of the 2014 ASAM Annual Award, and the 2018 ASAM Annual Educator of the Year Award.

    Richard K. Ries

    MD, DFASAM

    Richard K. Ries, MD, is Professor of Psychiatry, and Director of the Addictions Division in the Department of Psychiatry and Behavioral Sciences at the University of Washington School of Medicine in Seattle, Washington and Director of the Addiction Treatment services at Harborview Medical Center in downtown Seattle. Dr. Ries received his undergraduate degree from Stanford, medical degree from Northwestern Medical School and completed his psychiatric residency at the University of Washington, Seattle, where he was Chief Resident. 

    Dr. Ries is board-certified in Psychiatry by the American Board of Psychiatry and Neurology with Added Qualifications in Addiction Psychiatry, and the American Board of Addiction Medicine.  A Distinguished Fellow of the American Psychiatric Association and a Fellow of the American Society of Addiction Medicine, he is on the editorial board and a reviewer for several scientific journals and holds a number of research grants from the National Institute of Health. 

    He has published numerous articles and abstracts on topics related to treatment of persons with severe mental illness, with special emphasis on those with co-existing problems with alcohol or drugs, and was the chair and co-chair of TIPS 9 and 42 on Treatment of Persons with Co-occurring  Addiction and Mental Disorders published by the national Center of Substance Abuse Treatment (CSAT).  He is senior editor of  the key reference text:  Principles of Addiction Medicine (edition V, 2014), published by the American Society of Addiction Medicine, and a noted expert in the  field of Addictions.

    Carla Marienfeld

    MD

    Carla Marienfeld, MD, is an addiction psychiatrist and an Associate Clinical Professor of Psychiatry at University of California San Diego. Clinically, she focuses on the treatment of patients with substance use disorders and co-morbid psychiatric conditions. She previously worked at a large outpatient addiction treatment program serving over 5000 patients. Her academic interests focus on implementation research and large-data health outcomes for patients with substance use disorders. She attended Baylor College of Medicine in Houston, TX, where she completed the International Health Track, served nationally on the Board of Trustees of the American Medical Student Association (AMSA), and earned Alpha Omega Alpha (AOA) Medical Honors Society and Honors distinction. During psychiatry residency at Yale, she served as chief resident, a National Institute of Drug Abuse R25 Research Fellow, and as the resident representative to the Accreditation Council for Graduate Medical Education (ACGME), while also earning several awards and fellowships. She completed a fellowship in Addiction Psychiatry at Yale. During residency and her early faculty years, she founded and led the Yale Global Mental Health Program. She served as the site training director for the Yale New Haven Hospital Addiction Psychiatry Fellowship and supervised and taught medical students for psychiatry, residents for global mental health, and fellows for addiction psychiatry. She has come to UCSD to help in the development and implementation of a new Addiction Recovery and Treatment Program and a new Addiction Psychiatry Fellowship.

    Abigail J. Herron

    DO, DFASAM, FAPA

    Abigail J. Herron, DO, is the Director of Psychiatry and the Director of the Fellowship in Addiction Medicine at the Institute for Family Health.  She is board certified in adult psychiatry, addiction psychiatry and addiction medicine, and is an Assistant Professor of Psychiatry at the Icahn School of Medicine at Mt. Sinai.  

    Dr. Herron is a fellow of the American Psychiatric Association and a Distinguished Fellow of the American Society of Addiction Medicine.  She graduated from Wesleyan University and the University of Medicine and Dentistry of New Jersey School of Osteopathic Medicine.  Dr. Herron completed her psychiatry residency at St. Luke's and Roosevelt Hospitals, where she was also chief resident, and a clinical research fellowship in addiction psychiatry at Columbia University and the New York State Psychiatric Institute.  

    Her academic interests include integrated care, women’s health, and medical education.  She is the co-editor of the Addiction Casebook, and the editor-in-chief of ASAM’s Essentials of Addiction Medicine.  Dr. Herron is also in private practice in New York City. 

    Sharon Stancliff

    MD, FAAFP

    Sharon Stancliff, M.D. is the Medical Director of the Harm Reduction Coalition She oversees SKOOP, which provides overdose prevention services both directly in New York City and through education and capacity building nationally and internationally. Dr. Stancliff also consults on drug related problems for the AIDS Institute, New York State Department of Health and for several international organizations. 

    Dr. Stancliff graduated from the School of Medicine at University of California at Davis, did her Family Practice residency at the University of Arizona and completed the AIDS Institute-sponsored Nicolas Rango HIV Clinical Scholars Program at Beth Israel Medical Center in New York City. She is board certified in Family Medicine, a Fellow of the American Academy of Family Practice, and certified by the American Board of Addiction Medicine. She serves as secretary for the New York Society of Addiction Medicine.

    Timothy J. Wiegand

    MD, FACMT, FAACT, FASAM

    Tim Wiegand MD, DABAM, FACMT, FAACT was trained in internal medicine and completed fellowship training in Medical Toxicology at the University of California, San Francisco in 2006. He was the Medical Director of the Rochester Poison Center until 2010. Dr. Wiegand has been successful in developing a full time, bedside, medical toxicology consultation service and is very active in the practice of Addiction Medicine, having successfully completed his board certification recently. 

    In addition to his primary appointment as Associate Professor of Emergency Medicine at the University of Rochester School of Medicine & Dentistry in Rochester, NY, Dr. Wiegand serves as Medical Director for Huther Doyle Chemical Dependency Treatment Program in Rochester, NY and as a detoxification specialist for Syracuse Behavioral Health in Rochester, NY. 

    Dr. Wiegand serves on the New York Society of Addiction Medicine (NYSAM) Board of Directors as the Communication Committee Chair and he was recently elected to the American College of Medical Toxicology Board of Directors to begin a 3 year term in October, 2015. He currently serves as the chair of the Addiction Medicine Section for the American College of Medical Toxicology and he recently organized a very successful Addiction Medicine Academy for ACMT prior to their main Annual Scientific Meeting in Clearwater, Florida in March, 2015. Dr. Wiegand has presented for the ASAM Review Course on Pharmacology & Toxicology, MRO and drug testing principles at previous Review Course conferences.

    ACCME Accreditation Statement:

    The American Society of Addiction Medicine is accredited by the Accreditation Council for
    Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement:

    The American Society of Addiction Medicine designates this enduring material for a maximum of 6 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The ASAM CME Committee and Reviewers Disclosure Listing

    Name

    Commercial Interest

    What was received?

    For what role?

    Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO, Chair

    None

     

     

    Catherine Friedman, MD

    Vice Chair

    None

     

      

    Noel Ilogu, MD, MRCP, DFASAM

    None

     

     

    Hebert L. Malinoff, MD, FACP, DFASAM

    None

     

     

    Edwin A. Salsitz, MD, DFASAM

    None

     

     

    John C. Tanner, DO, DABAM, DFASAM, CCFC, MRO

    Indivior

    BDSI

    Honorarium

    Honorarium

    Speaker

    Consultant/Speaker

      The ASAM Review Course Program Planning Committee Disclosure Listing

    Name

    Commercial Interest

    What was received?

    For what role?

    Petros Levounis, MD, MD, DFASAM

    None

     

     

    Abigail Herron, DO, DFASAM, FAPA

    None

     

     

    Timothy K. Brennan, MD, MPH, FASAM

    None

     

     

    David Galbis-Reig, MD, DFASAM

    Abbot Pharmaceuticals

     

    AbbVie

     

     

    Cortex Pharmaceuticals

     

    GW Pharmaceuticals

     

    Hospira

     

     

    Pfizer, INC

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

    Stock Options

     

     

    Stock Options

    (spouse)

     

    Stock Owned through IRA Rollover Account

    Stock Owned through IRA Rollover Account

    Stock Options

    (Spouse)

     

    Bonds in IRA

    Carla Marienfield, MD

    None

     

     

    Ricardo Restrepo, MD, MPH

    None

     

     

    Edwin A. Salsitz, MD, DFASAM

    None

     

     

    Erin Zerbo, MD

    None

     

     

    The ASAM Review Course Faculty Member Disclosure Listing

    Name

    Commercial Interest

    What was received?

    For what role?

    Petros Levounis, MD, MD, DFASAM

    None

     

     

    Abigail Herron, DO, DFASAM, FAPA

    None

     

     

    Timothy K. Brennan, MD, MPH, FASAM

    None

     

     

    Jeffrey DeVido, MD, MTS

    Philip Morris

     

     

    Altria

    Ownership Interest

     

    Ownership Interest

    Equity Shareholder

     

    Equity Shareholder

    Paul H. Earley, MD, DFASAM

    Alkermes

     

    Georgia PHP, INC

     

    Earley Counsultancy, LLC

     

    DynamiCare Health, INC

    Honoraria

     

    Salary

     

     

    Salary

     

     

     

    Salary

    Speaker

     

    Medical Director

     

     

    Principal

     

     

     

    Speaker

    James W. Finch, MD, DFASAM

    Orexo Pharmaceuticals

     

    Indivior Pharmaceuticals

    Honoraria

     

     

    Honoraria

    Speaker

     

     

    Speaker

    Marc Fishman, MD, DFASAM

    Alkermes

     

     

    US WorldMeds

     

     

     

     

    MediaRez

    Salary

     

     

    Salary

     

     

     

     

    Research Funding

    Consultant; Advisory Board

     

    Consultant; Advisory Board; Principal Research Investigator

     

    Principal Research Investigator

    David Galbis-Reig, MD, DFASAM

    Abbot Pharmaceuticals

     

    AbbVie

     

     

    Cortex Pharmaceuticals

    GW Pharmaceuticals

     

    Hospira

     

     

    Pfizer, Inc

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

    Stock Options

     

     

    Stock Options

    (spouse)

    Stock Owned through IRA Rollover Account

    Stock Owned through IRA

     

    Rollover Account

    Stock Options

    (Spouse)

    Bonds in IRA

    Leslie Hayes, MD

    None

     

     

    Carla Marienfield, MD

    None

     

     

    Ricardo Restrepo, MD, MPH

    None

     

     

    Richard Ries, MD, DFASAM

    None

     

     

    Edwin A. Salsitz, MD, DFASAM

    None

     

     

    Sharon Stancliff, MD

    None

     

     

    Timothy J. Wiegand, MD, FACMT, FAACT, FASAM

    None

     

     

    Erin Zerbo, MD

    None

     

     

  • The ASAM Review Course in Addiction Medicine 2018

    Contains 25 Product(s)

    The ASAM Review Course in Addiction Medicine is widely recognized as the essential primer for physicians and clinicians preparing for a career in addiction medicine, as well as for primary care providers who wish to increase their skills in identifying and managing patients whose medical problems are caused or exacerbated by substance use disorders.

    image

    Overview

    The ASAM Review Course in Addiction Medicine is widely recognized as the essential primer for physicians and clinicians preparing for a career in addiction medicine, as well as for primary care providers who wish to increase their skills in identifying and managing patients whose medical problems are caused or exacerbated by substance use disorders.

    The course offers two and a half days of sessions which are mapped to the addiction medicine exam blueprint of topics for the exam and features an outstanding faculty. Over 600 professionals attend this popular course each time it is offered. ASAM’s Review Course has had a major impact on advancing a common base of scientific knowledge among physicians and other healthcare professionals.

    Learning Objectives

    Upon completion, participants should be able to:

    1. Demonstrate practical knowledge on the neurobiology of addiction and articulate its activity in terms useful in a clinical setting
    2. Describe the effects of alcohol, tobacco and other drugs in both tolerant and non-tolerant individuals
    3. Describe the process for diagnosing addiction and differentiating the symptoms of addiction from those of other medical or psychiatric disorders
    4. Explain the various pharmacologic and psychosocial treatments for addictive disorders and describe the factors that should be considered in selecting a treatment modality to match the needs of a specific patient
    5. Describe the precipitants of relapse and current evidence-based practices to prevent and manage relapse


    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The ASAM CME Committee and Reviewers Disclosure Listing

    First Name Commercial Interests Compensation Received For what Role?
    Timothy Brennan MD, MPH, FASAM None
    Jeffrey DeVido MD Altria/Philip Morris Stock Inheritance
    Paul Earley MD, DFASAM Alkermes, Inc; DynamiCare Health, Inc honoraria; Salary Speaker; VP of Medical Affairs 
    James Finch MD, DFASAM None

    Marc Fishman MD, DFASAM US World Meds; Alkermes consulting fee, travel; honoraria Consultant; Advisory board
    David Galbis-Reig MD, DFASAM Ascension Wisconsin All Saints; Abbvie; Hospira; RespireRX Pharmaceuticals; Abbott Pharmaceuticals; Pfizer Bond Stock& Bond in Retirement IRA; Stock Options; Ownership Interests  Owner; Advisory board; PI; Consultant
    Adam Gordon, MD, MPH None
    Leslie Hayes, MD None
    Abigail Herron DO, DFASAM None
    Petros Levounis MD, MA, FASAM None
    Carla Marienfeld MD None
    Ricardo Restrepo MD, MPH, FASAM None
    Richard Ries MD, DFASAM None
    Edwin Salsitz MD, DFASAM None
    Sharon Stancliff MD, FASAM None
    Timothy Wiegand MD, FACMT, FAACT None
    Erin Zerbo, MD None

    ACCME Accreditation Statement:

    The American Society of Addiction Medicine is accredited by the Accreditation Council for
    Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement:

    The American Society of Addiction Medicine designates this live activity for a maximum of 20.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    American Academy of Family Physicians: 

    This Live activity, The 2018 ASAM Review Course in Addiction Medicine & Pre-Courses, with a beginning date of 07/25/2018, has been reviewed and is acceptable for up to 27.50 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABAM Transitional Maintenance of Certification Program (Tmoc)

    This course has been approved by The American Board of Addiction Medicine (ABAM).  Physicians enrolled in the Transitional Maintenance of Certification (Tmoc) Program can apply a maximum of 20.5 AMA PRA Category 1 Credits

    American Psychological Association (APA)

    The American Society of Addiction Medicine (ASAM) Continuing Medical Education (CME) has been approved for renewal of certification by the APA College of Professional Psychology. ASAM CME credits may be applied toward the APA’s “Certificate of Proficiency in the Treatment of Alcohol and Other Psychoactive Substance Use Disorders.”

    Continuing Education Credits (CEUs)

    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    CME Committee Members

    • Catherine Friedman, MD, FASAM, Chair
    • R. Jeffrey Goldsmith, MD, DLFAPA, DFASAM
    • Adam J. Gordon, MD, MPH, FACP, DFASAM
    • Zwaantje Hamming, FNP-C, CARN-AP
    • Noel Ilogu, MD, MRCP, FASAM
    • Herbert L. Malinoff, MD, FACP, DFASAM
    • Edwin A. Salsitz, MD, DFASAM

    Staff - Sandy Metcalfe; Arlene Deverman, MA, CAE, CFRE; Marcia Jackson, PhD

    CME Committee, Program Planning Committee and Faculty Disclosure Information

    In accordance with the disclosure policies of the American Society of Addiction Medicine (ASAM) and the Accreditation Council for Continuing Medical Education (ACCME), the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These polices include resolving all conflicts of interest between the CME Committee, planning committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All planning committee members and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The ASAM CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    Upon completion, participants should be able to:

    1. Demonstrate practical knowledge on the neurobiology of addiction and articulate its activity in terms useful in a clinical setting.
    2. Describe the effects of alcohol, tobacco and other drugs in both tolerant and non-tolerant individuals.
    3. Describe the process for diagnosing addiction and differentiating the symptoms of addiction from those of other medical or psychiatric disorders.
    4. Explain the various pharmacologic and psychosocial treatments for addictive disorders and describe the factors that should be considered in selecting a treatment modality to match the needs of a specific patient.
    5. Describe the precipitants of relapse and current evidence-based practices to prevent and manage relapse.

    The ASAM Review Course in Addiction Medicine provides an up-to-date review of the core content of addiction medicine for:

    • Physicians preparing for the ABPM Board Certification/Recertification Examination in addiction medicine
    • Addiction specialists seeking a "refresher" course that incorporates recent developments in addiction science and practice
    • Non-specialist physicians and other healthcare professionals needing the knowledge to identify and manage problems related to substance use disorders for their patients 
  • Pain Management and Opioids: Balancing Risks and Benefits (2.5 CME)

    Contains 5 Component(s), Medical Credits Offered Recorded On: 07/25/2018

    Earn 2.5 AMA PRA Category 1 Credit(s) while reviewing prescribing habits and examine the difference between extended release/long acting medications to help ensure patient safety and effective pain management.

    image

    The misuse of extended-release and long-acting (ER/LA) opioids is a major public health problem. Centers for Disease Control and Prevention reported the following:

    • From 2000 to 2015 more than half a million people died from drug overdoses.
    • 91 Americans die every day from an opioid overdose.

    The CO*RE/ASAM Pain Management and Opioids: Balancing Risks and Benefits addresses the opioid public health crisis. This comprehensive course was developed by renowned experts from Collaborative for REMS Education (CO*RE) and incorporates all six units outlined in FDA blueprint for safe opioid prescribing. The updated course also provides necessary context for safe opioid prescribing by discussing biopsychosocial aspects of pain, the newest clinical guidelines on the treatment of chronic pain, and state policies about prescribing opioids.

    Learners will be able to:

    1. Accurately assess patients with pain for consideration of an opioid trial
    2. Establish realistic goals for pain management and restoration of function
    3. Initiate opioid treatment (IR and ER/LA) safely and judiciously, maximizing efficacy while minimizing risks
    4. Monitor and re-evaluate treatment continuously; discontinue safely when appropriate
    5. Counsel patients and caregivers about use, misuse, abuse, diversion, and overdose
    6. Educate patients about safe storage and disposal of opioids
    7. Demonstrate working knowledge and ability to access general and specific information about opioids, especially those used in your practice.

    Edwin A. Salsitz

    MD, DFASAM

    Dr. Edwin A. Salsitz has been an attending physician in the Mount Sinai Beth Israel , Division of Chemical Dependency, New York City, since 1983, and is an Assistant Professor of Psychiatry at the Mount Sinai School of Medicine. He is the principal investigator of the Methadone Medical Maintenance (office-based methadone maintenance) research project. 

    Dr. Salsitz is certified by the American Board of Addiction Medicine (ABAM), as well as by the Board of Internal Medicine and Pulmonary Disease. He has published and lectures frequently on addiction medicine topics.Dr. Salsitz is a course director for ASAM sponsored buprenorphine trainings,and is a mentor in the PCSS-MAT mentoring program. He has co-chaired the ASAM Review Course, the ASAM Common Threads Course, the ASAM State of the Art course and is a reviewer for the Journal of Addiction Medicine and Drug and Alcohol Dependence. He is the chair of the ASAM REMS course on safe and effective prescribing of opioids. 

    Dr. Salsitz was the Co-chair of the ASAM CME committee and Chair of the New York Society of Addiction Medicine CME and Education committee. Dr. Salsitz is a member of the medical advisory panel, for the New York State Office of Alcohol and Substance Abuse Services.  Dr. Salsitz is the recipient of the 2014 ASAM Annual Award, and the 2018 ASAM Annual Educator of the Year Award.

    CME Information and Disclosure Listing

    The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. ASAM has been awarded the highest level of Accreditation with Commendation by the ACCME as a provider of continuing medical education.  

    The American Society of Addiction Medicine designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

    In accordance with the disclosure policies of the American Society of Addiction Medicine (ASAM) and the Accreditation Council for Continuing Medical Education (ACCME), the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the Medical Education Council, the CME Committee, program planning committees and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of the activity. All program planning committee members and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The ASAM CME Committee has reviewed these disclosures and determined that the program planning committee and faculty relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.  

    ASAM CME Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Catherine R. Friedman, MD, FAPA, DFASAM, Chair

    None

     

     

    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAM

    None

     

     

    Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO

    None

     

     

    Zwaantje Hamming, FNP-C, CARN-AP

    None

     

     

    Noel Ilogu, MD, MRCP, DFASAM

    None

     

     

    Hebert L. Malinoff, MD, FACP, DFASAM

    None

     

     

    Edwin A. Salsitz, MD, DFASAM

    None

     

     

    ASAM Staff and Consultants:

     

     

     

    Arlene C. Deverman, MA, CAE, CFRE

    None

     

     

    Marcia Jackson PhD

    None

     

     

    Sandy Metcalfe

    None

     

     

    Program Planning Committee

    Faculty

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Herbert Malinoff, MD, FACP, DFASAM

    None

     

     

    Yngvild Olsen, MD, MPH

    None

     

     

    Theodore Parran, MD, FACP

    None

     

     

    Edwin Salsitz, MD, DFASAM

    None

     

     

    R. Corey Waller, MD, MS, FACEP

    None

     

     

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Edwin A. Salsitz, MD, DFASAM

    None

     

     

      ASAM CME Committee Reviewers

    ASAM Medical Education Council

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Jacob Bobrowski, MD, FAAFP

    None

     

     

    Anthony H. Dekker, DO, DFASAM

    None

     

     

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Peter Selby, MBBS, CCFP, FCFP, MHSc, DipABAM, DFASAM, Chair

    Pfizer

    Johnson & Johnson

    Pfizer Canada

    Grant funding

    Consulting Fees

    Consulting Fees

     Principal Investigator

    Consulting

    Consulting

    Daniel Alford, MD, MPH

    None

     

     

    Michael Fingerhood, MD, FACP, FASAM

    None

     

     

    Catherine R. Friedman, MD, FAPA, DFASAM

    None

     

     

    Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO

    None

     

      

    Miriam S. Komaromy, MD, FACP, DFASAM

    None

     

     

    Edwin A. Salsitz, MD, DFASAM

    None

     

     

    Mark P. Schwartz, MD, DFASAM

    None

     

     

    Mark A. Weiner, MD, FASAM

    None

     

     

    ASAM Staff and Consultants:

     

     

     

    Arlene C. Deverman, MA, CAE, CFRE

    None

     

     

    Marcia Jackson PhD

    None

     

     

    Jennifer L. Butchart

    None

     

     

    Penny S. Mills, MBA

    None

     

     

     

    Acknowledgement

    Presented by ASAM, a member of the Collaborative on REMS Education (CO*RE), 10 interdisciplinary organizations working together to improve pain management and prevent adverse outcomes.

    RPC Commercial Support Disclosure Statement

    This educational activity is supported by an independent educational grant from the ER/LA Opioid Analgesic REMS Program Companies. Please see this link for a listing of the member companies. This activity is intended to be fully compliant with the ER/LA Opioid Analgesic REMS education requirements issued by the US Food & Drug Administration.

    This course is not intended to advocate for the use of ER/LA Opioids, but to ensure proper education about safe prescribing practices should a medical provider determine that ER/LA Opioids are the best course of treatment.

  • Board Exam Study Tool (BEST) - 2018 (12 CME)

    Contains 5 Component(s), Medical Credits Offered

    Earn 12 AMA PRA Category 1 Credit(s)™ while learning from the BEST. This study tool helps prepare physicians for the ABPM certification/re-certification examination utilizing an interactive and engaging format.

    image



    The ASAM Board Examination Study Tool (BEST) helps prepare physicians for the ABPM certification/re-certification examination utilizing an interactive and engaging format. 

     

    This powerful study tool includes:

     

    • Bank of 600 self-assessment questions reviewed for accuracy by addiction medicine experts
    • Content derived from the ABPM Exam Blueprint for effective study guidance
    • Excerpts and highlights from ASAM’s Essentials of Addiction Medicine and Principles of Addiction Medicine
    • Glossary of important terms and definitions
    • Additional resources recommended by Review Course faculty and experts for each topic
    • 12 CME Credits upon completion
    • Fully searchable functionality and content
    • Access to the BEST 24/7 online at ASAM's e-Learning Center


    Live attendees of the 2018 ASAM Review Course in Addiction Medicine in Dallas, TX receive the 2018 BEST complimentary with registration. 

    Goals and Objectives

    Upon completion of this education activity, participant should be able to:

    • Differentiate between important terms and definitions in the field of Addiction Medicine.
    • Distill knowledge on key points from the text, the Principles of Addiction Medicine, 5th edition and course slides
    • Appraise addiction patient cases and respond accurately to questions about next steps and treatment options.
    • Employ knowledge gained in the educational sections of the BEST to respond accurately to self-assessment questions.

    Participants of the 2018 ASAM Review Course in Addiction Medicine and other physicians who are preparing for the ABPM Certification Exam in Addiction Medicine.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 12 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    First Name Commercial Interests Compensation Received For what Role?
    Timothy Brennan MD, MPH, FASAM None
    Jeffrey DeVido MD Altria/Philip Morris Stock Inheritance
    Paul Earley MD, DFASAM Alkermes, Inc; DynamiCare Health, Inc honoraria; Salary Speaker; VP of Medical Affairs 
    James Finch MD, DFASAM None

    Marc Fishman MD, DFASAM US World Meds; Alkermes consulting fee, travel; honoraria Consultant; Advisory board
    David Galbis-Reig MD, DFASAM Ascension Wisconsin All Saints; Abbvie; Hospira; RespireRX Pharmaceuticals; Abbott Pharmaceuticals; Pfizer Bond Stock& Bond in Retirement IRA; Stock Options; Ownership Interests  Owner; Advisory board; PI; Consultant
    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAM None
    Adam Gordon, MD, MPH None
    Leslie Hayes, MD None
    Abigail Herron DO, DFASAM None
    Petros Levounis MD, MA, FASAM None
    Carla Marienfeld MD None
    Ricardo Restrepo MD, MPH, FASAM None
    Richard Ries MD, DFASAM None
    Edwin Salsitz MD, DFASAM None
    Sharon Stancliff MD, FASAM None
    Timothy Wiegand MD, FACMT, FAACT None
    Erin Zerbo, MD None
  • ASAM 49th Annual Conference - Innovations in Addiction Medicine and Science - 2018 (64.5 CME)

    Contains 49 Product(s)

    The nation’s premiere conference on the latest science, research, best practices and innovations in addiction medicine.


    image

    The ASAM 49th Annual Conference is the nation’s premiere conference on the latest science, research, best practices and innovations in addiction medicine. The 2018 program includes more education offerings such as; seven concurrent sessions offerings at a time instead of six, three pre-conference courses instead of two.  There will also be three Plenary Sessions that include the popular Opening Plenary Session and Policy Plenary Session and new this year the National Perspectives Plenary Session moderated by the ASAM president with leaders from national federal agencies. There will be other exciting changes to provide learning in a more interactive, casual and fun environment. 

    Learning Objectives:

    At the conclusion of the conference, participants should be able to:

    • Identify and describe the new developments affecting the science, policy, and clinical practice of addiction medicine.
    • Compare presented clinical guidelines/best practices with the participant's current practice and identify strengths or gaps.
    • Analyze new research and science to develop practical applications for treatment or further research.
    • Explain recent or upcoming policy changes and identify implications or areas for provider involvement.
    • Create a network of professionals or a set of resources that can be used to support the participant's practice.


    Accreditation Council for Continuing Medical Education (ACCME)

    The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

    The ASAM 49th Annual Conference - Innovations in Addiction Medicine and Science

    The American Society of Addiction Medicine designates this enduring material for a maximum of 64.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABAM Transitional Maintenance of Certification (Tmoc)

    This course has been approved by the American Board of Addiction Medicine (ABAM).  Physicians enrolled in the ABAM Transitional Maintenance of Certification (Tmoc) Program can apply a maximum of 64.5 AMA PRA Category 1 Credit(s)™ for completing the The ASAM 48th Annual Conference – Innovations in Addiction Medicine and Science.

    American Psychological Association (APA)

    The American Society of Addiction Medicine (ASAM) Continuing Medical Education (CME) has been approved for renewal of certification by the APA College of Professional Psychology. ASAM CME credits may be applied toward the APA’s “Certificate of Proficiency in the Treatment of Alcohol and Other Psychoactive Substance Use Disorders.”

    Continuing Education Credits (CEUs)

    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    CME Committee Members

    • Catherine Friedman, MD, FASAM, Chair
    • R. Jeffrey Goldsmith, MD, DLFAPA, DFASAM
    • Adam J. Gordon, MD, MPH, FACP, DFASAM
    • Zwaantje Hamming, FNP-C, CARN-AP
    • Noel Ilogu, MD, MRCP, FASAM
    • Herbert L. Malinoff, MD, FACP, DFASAM
    • Edwin A. Salsitz, MD, DFASAM

    Staff - Sandy Metcalfe; Arlene Deverman, MA, CAE, CFRE; Marica Jackson, PhD

    CME Committee, Program Planning Committee and Faculty Disclosure Information

    In accordance with the disclosure policies of the American Society of Addiction Medicine (ASAM) and the Accreditation Council for Continuing Medical Education (ACCME), the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These polices include resolving all conflicts of interest between the CME Committee, planning committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All planning committee members and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The ASAM CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    Who Should Attend:

    • Physicians and Clinicians
    • Researchers and Academics
    • Counselors and Students
    • Other Health Care Professionals 

    dedicated to increasing access and improving the quality of addiction treatment and care.

  • From Overdose to Engagement: Working with First Responders and Emergency Departments (1 CME)

    Contains 4 Component(s), Medical Credits Offered

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning how professionals in Indiana's Project POINT have been removing as many barriers as possible to help patients get the services they desire, as well as, getting and then, maintaining engagement in treatment, from this conference recording at The ASAM 49th Annual Conference (2018).

    (1.0 CME) In this conference recording from the 2018 Annual Conference, you will learn about how emergency department (ED) visits for opioid overdose have increased dramatically over the last several years, mirroring trends in overdose related mortality (1). In Indianapolis alone, our ambulance service—Indianapolis Emergency Medical Services—responded to over 2,000 opioid overdoses in 2016 and are on track to outpace that in 2017. Many local public health and safety agencies have championed increased access to naloxone and participated in trainings making it more widely available and accepted by first responders and community members (2). In Indianapolis, we created project POINT to help link those surviving an opioid overdose with the highest quality emergency care including warm hand offs to on-going treatment. Methods: We convened a group of experts and key stakeholders in our hospital system/community and undertook a quality improvement process to improve the care of overdose survivors while in the ED and through their transition to longitudinal care. Results: We developed a set of core ED services and a plan to implement each of them. Core ED services included: 1) brief assessment by a specialty trained outreach team member (ideally a recovery coach), 2) rapid HIV/hepatitis C testing, 3) naloxone teaching and provision, 3) harm reduction counseling, 4) referral to appropriate next level of care and 5) rapid ED follow up focused on recovery support, increasing/supporting motivation and overcoming logistical barriers. We also created a network of providers who were willing and able to accept our referrals and worked with them to optimize the referral process. 

    Conclusions: With the growing opioid epidemic, EDs and EMS systems are looking for novel and effective ways to reduce mortality and help bridge patients into recovery. EDs and EMS systems are used to working at all hours, in austere conditions with complex and often critically ill patients. We offer an expansive and largely untapped network of providers which could be brought to bear on this epidemic. Project POINT is one example of how the ED can help drive incremental change—even in areas of the country where access to high quality MAT is limited.

    Melissa A. Reyes

    MA, CRC

    Melissa Reyes, M.A., CRCMelissa Reyes completed her B.A. in Criminal Justice and Criminology at Ball State University in Muncie, IN. Following graduation, she worked as a case manager for the Madison Co. Problem Solving Courts for two years and was involved with both the Drug Court and Mental Health Court. In 2014, she then pursued her M.A. degree at Michigan State University in Rehabilitation Counseling. Melissa transitioned back to her home state of IN with the acceptance of a care coordinator position with Midtown Adult Addictions in Indianapolis, IN in September of 2016. The position was the forerunner of its kind for both organizations, and required constructing a unique collaboration between the community mental health center and Eskenazi Health ED; the area’s safety-net hospital. By January 2017, Melissa had accepted the role of Program Director for Project POINT (Planned Outreach,Intervention, Naloxone, and Treatment). Initially, POINT focused exclusively on providing referrals with warm handoffs, but Melissa expanded the scope and pursued a more holistic approach. This included promoting the start of implementing harm reduction counseling, rapid HIV/HCV testing as well as take home naloxone kits. In March of 2017, POINT expanded to include peer recovery coaching, and Melissa not only oversees the implementation of this new role, but also develops the training and supervision plan. Most recently, in January 2018, Melissa was offered and accepted the position of Project Director, Project POINT and Mobile Project POINT.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Treating Youth with Opioid Addiction: Cases and Controversies (1.5 CME)

    Contains 4 Component(s), Medical Credits Offered

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning how to treat youth with opioid addiction while employing developmentally specific approaches, using relapse prevention medication (MAT), from this conference recording from The ASAM 49th Annual Conference (2018).. The session also includes when and how to involve families, as well as a discussion on issues in confidentiality and the use of various levels of care.

    (1.5 CME) In this conference recording from the 2018 Annual Conference, you will learn about more about treating youth with opioid addiction through cases and controversies. Young people are disproportionately affected by the current opioid epidemic, with catastrophic consequences for youth and their families. Despite the urgent need, there is a lack of consensus about treatment approaches for youth. Many practitioners have questions, and struggle with this “mysterious” and difficult to engage population. This workshop will feature an interactive, case-based format. Workshop leaders will present 4-5 cases with background and treatment course, each punctuated by “what would you do next…” management questions for guided discussion at several pivotal decision points in the course. Cases are chosen to reflect real world concerns and clinical conundrums, key learning objectives, practice debates and controversies. 

    The goal is to engage participants in a lively conversation about developmentally-informed strategies, approaches, and treatment options in the treatment of this critical target population. 

    Featured cases

    • 18 M at 5th episode of residential detoxification who has been unable to sustain continuing outpatient care despite previous course of buprenorphine.
    • 19 F who becomes pregnant during treatment with extended release naltrexone.
    • 20 M in outpatient treatment, abstinent from opioids on buprenorphine, but struggling with cocaine and other non-opioid substances, opposes communication with family.
    • 17 F who presents in crisis to residential treatment seeking detoxification, and struggles with the process of decision making around recommendations for and choice of relapse prevention medications (buprenorphine vs extended release naltrexone).
    • 18 M with sickle cell anemia with repeated relapses despite multiple treatment levels of care, including multiple attempts at outpatient buprenorphine treatment under various programmatic conditions.

    The case discussions will cover a range of questions, including: 

    1. developmentally specific approaches to treatment of adolescents and young adults with OUDs; 
    2. use of relapse prevention medication (MAT) in youth; 
    3. the role of families, when and how to involve them; 
    4. confidentiality; use of various levels of care; 
    5. the impact of other substance use disorders (primarily cannabis and alcohol); 
    6. delivery models for medications and psychosocial treatment modalities; and others.

    Marc Fishman

    MD, DFASAM

    Marc Fishman MD is a specialist in addiction psychiatry and addiction medicine. He is a member of the faculty of the Department of Psychiatry at the Johns Hopkins University School of Medicine. He leads Maryland Treatment Centers, which offers programs for residential and outpatient treatment of drug-involved and dual-diagnosis adolescents and adults. He has written and lectured widely on a variety of topics including youth treatment, placement and treatment matching strategies, co-occurring disorders, and medication treatment for addiction. His research focus has been in treatment of opioid use disorders in youth. 

    Dr. Fishman served as a co-editor for the most recent editions of ASAM's Patient Placement Criteria, leading the adolescent section, and served as the chief editor for the ASAM PPC Supplement on Pharmacotherapies for Alcohol Use Disorders. He is the chair of the Adolescent Committee for ASAM. He is a Past President of the Maryland Society of Addiction Medicine, and also a current member of the Board.

    Bikash Sharma

    MD

    Bikash Sharma, MD is currently a medical director for adult services at the Mountain Manor Baltimore, Maryland Treatment Centers.  Dr. Sharma has board certifications with the American Board of Psychiatry and Neurology as well as the American Board of Addiction Psychiatry.  He has been published in numerous journals where he has written about opioid use disorders, and alcohol and substance use in African Americans.  


    Ann Bruner

    MD

    Ann Bruner, MD is a Medical Director, who treats youth at the Mountain Manor Baltimore, Maryland Treatment Centers.  Dr. Bruner is referenced as an author or co-author in dozens of peer-reviewed journals in the Journal of Adolescent Health, and a contributor to the Clinical Handbook of Adolescent Addiction.  

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Webinar: Addiction Medicine: The Next Generation (1 CME)

    Contains 4 Component(s), Medical Credits Offered

    This webinar will cover what an addiction medicine specialist looks like, the different settings an addiction medicine clinician can work in, and the future pathways physician will have to become board-certified in Addiction Medicine.

    Addiction Treatment Week

    This on-demand webinar will cover what an addiction medicine specialist looks like, the different settings an addiction medicine clinician can work in, and the future pathway physician have to become ADM certified.

    This webinar is ideal for pre-medical student, medical students, residents, and medical school administrators.

    Upon completion of this activity, participants will be able to:

    1. Explain recent updates to the Addiction Medicine field.
    2. Describe how changes to the certification process further integrate addiction treatment into the health care system.
    3. Appraise which pathways they are eligible to the ABPM ADM exam. 
    4. Define the different pathways a physician can take from to the ABPM exam. 
    5. Identify the need for more physicians to become board-certified in addiction medicine. 
    6. Explain the basic components of an addiction medicine specialist. 

    Louis E. Baxter, Sr.

    MD, DFASAM

    Dr. Louis E. Baxter, Sr., MD, DFASAM is a Past ASAM President and is the President &CEO of thr Professional Assistance Program of New Jersey, Inc.

    Dr. Baxter is a certified in Addiction Medicine by the American Board of Addiction Medicine and formerly served on the Board of Directors. Dr. Baxter has served and chaired many government advisory committees and panels which include SAMHSA, NIDA, CSAT, NIAAA, and a Presidential Advisor through ONDCP since the Clinton Administration.

    Dr. Baxter has served the State of New Jersey in various capacities serving on the Governor's Council for Drug and Alcohol Addiction, Medical Director for the Division of Addiction Services, and most recently as the Addiction Medicine Consultant for the Division of Mental Health and Addiction Services. He has held academic appointments as Assistant Clinical Professor of Medicine for former University Medicine & Dentistry and now currently with Rutgers New Jersey Medical School in Newark, NJ. Dr. Baxter is serving as Co-Director if the Addiction Medicine Fellowship Program at Howard University Medical School and Hospital.

    Helen E. Jack

    MD

    Helen Jack is a fourth year student at Harvard Medical School. In medical school, her research has focused on how lay health workers, including recovery coaches and community health workers, can contribute to care access and outcomes. She also helps organize the Student Coalition on Addiction, a group of medical students from across Massachusetts engaged in advocacy on addiction medicine education and access to treatment services. She holds a Visiting Researcher position at the Institute of Psychology, Psychiatry, and Neuroscience at King's College London. With KCL, she conducts mental health systems research in Zimbabwe and works on a Wellcome Trust-funded project to build mental health research capacity in southern Africa. Helen graduated from Yale University in 2012. Following graduation, she got a second BA in Philosophy, Politics, and Economics at Oxford University as a Rhodes Scholar. 

    Anna Lembke

    MD, FASAM

    Dr. Anna Lembke is currently an Associate Professor of Psychiatry and Behavioral Sciences at Stanford University School of Medicine.  She is a diplomate of the American Board of Psychiatry and Neurology, a diplomate of the American Board of Addiction Medicine, the Program Director for the Stanford University Addiction Medicine Fellowship, and Chief of the Stanford Addiction Medicine Dual Diagnosis Clinic.

    She has published peer-reviewed articles, chapters, and commentaries, including in the New England Journal of Medicine, the Journal of the American Medical Association, the Journal of General Internal Medicine, and Addiction. Dr. Lembke sees patients, teaches, and does research. She is the author of a book on the prescription drug epidemic: “Drug Dealer, MD: How Doctors Were Duped, Patients Got Hooked, and Why It’s So Hard to Stop” (Johns Hopkins University Press, October 2016).


    Addiction Medicine:  The Next Generation Webinar Planning Committee 

    Name

    Disclosure

    Peter L. Selby MBBS, CCFP, FCFP, MHSc, DFASAM

    Johnson and Johnson: Consultant/Advisory Board, Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support;Pfizer: Consultant/Advisory Board, Other Research Support includes receipt of drugs, supplies, equipment

    Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO

    No Financial Relationships or Conflicts of Interest

    Mark P. Schwartz, MD, FAAFP, DFASAMNo Financial Relationships or Conflicts of Interest
    Louis E. Baxter, MD, DFASAMNo Financial Relationships or Conflicts of Interest
    Helen JackNo Financial Relationships or Conflicts of Interest
    Anna Lembke, MD, FASAMNo Financial Relationships or Conflicts of Interest

    ASAM CME Committee 

    Name

    Disclosure

    Catherine Friedman, MD, FAPA, FASAM, Chair

    No Financial Relationships or Conflicts of Interest

    Adam J. Gordon, MD, MPH, FACP, DFASAM

    No Financial Relationships or Conflicts of Interest

    Noel Ilogu, MD, MRCP, DFASAM

    No Financial Relationships or Conflicts of Interest

    Herbert L. Malinoff, MD, FACP, DFASAM

    No Financial Relationships or Conflicts of Interest

    Edwin A. Salsitz, MD, DFASAM

    No Financial Relationships or Conflicts of Interest

    John C. Tanner, DO, DABAM, DFASAM, CCFC, MRO

    Indivior, Honorarium, Speaker; BDSI, Honorarium, Consultant/SpeakerCommercial Interest Definition


    A commercial interest is any entity producing, marketing, re-selling or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.

     

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Webinar: Pathways to the Addiction Medicine Subspecialty (1 CME)

    Contains 4 Component(s), Medical Credits Offered

    This webinar will begin with an overview of the current state of the addiction epidemic, then move onto other topics including the gap in addiction treatment, the role physicians can play to help close the gap, and the importance, as well as how to apply for the ADM exam. Earn 1 CME while learning how to become board-certified in Addiction Medicine.

    Addiction Treatment Week

    This on-demand webinar will begin with an overview of the current state of the addiction epidemic and the huge gap in addiction treatment. It will then move on to the role physicians can play to help close this gap, and the importance to sit for the ABPM Addiction Medicine exam. The webinar will then move on to a representative from ABPM discussing the details of how physicians can apply for the ADM exam and any “lessons learned” from last year. 

    This webinar is ideal for any physician interested in addiction medicine, ABAM Diplomates, DATA 2000 waivered physicians, medical directors, and others.

    Upon completion of this activity, participants will be able to:

    1. Explain recent updates to the Addiction Medicine field.
    2. Describe how changes to the certification process further integrate addiction treatment into the health care system.
    3. Appraise which pathways they are eligible to the ABPM ADM exam. 
    4. Define the different pathways a physician can take from to the ABPM exam. 
    5. Identify the need for more physicians to become board-certified in addiction medicine. 

    Shawn A. Ryan

    MD, MBA, FASAM

    Shawn A. Ryan, MD, MBA is an Dual Board Certified Emergency Physician as well as Addiction Specialist.  He is currently an assistant professor, Department of Emergency Medicine, University of Cincinnati, and President & CMO of BrightView Health.  Dr. Ryan is currently practicing addiction medicine treatment in Cincinnati, is published on this issue, and also serves on many regional, state, and national committees addressing this complicated subject.  Dr. Ryan is President of the Ohio Society of Addiction Medicine and the Chair of Payer-Relations for ASAM and he spends a significant amount of time working with large commercial payers and Medicaid administrators on current and future payment strategies.

    Steven Daviss

    MD, DFAPA

    Steven Daviss, MD, DFAPA is a physician, double-boarded in Psychiatry and in Psychosomatic Medicine, which is the intersection of primary care and psychiatry. He is currently a senior medical advisor for the Office of the CMO at SAMSHA.  He is the past Chair of the Department of Psychiatry at Baltimore Washington Medical Center (2004-2014), and is a Clinical Assistant Professor in the University of Maryland School of Medicine, where he also attended medical school. He trained at the University of Pittsburgh Medical Center at Western Psychiatric Institute and Clinic. He completed an NIMH-funded clinical research fellowship in schizophrenia at the Maryland Psychiatric Research Center.

    Michael F. Weaver

    MD, DFASAM

    Dr. Michael Weaver is Professor of Psychiatry and Medical Director of the Center for Neurobehavioral Research on Addiction at The University of Texas McGovern Medical School at Houston. He completed a Residency in Internal Medicine and a Clinical Research Fellowship in Addiction Medicine at Virginia Commonwealth University. He is involved in patient care, medical education, and research. Dr. Weaver has multiple publications in the field of addiction medicine. He treats patients at the Innovations Addiction Treatment Clinic at the Texas Medical Center in Houston, which provides medication-assisted treatment. He is the Sub-Board Chair for Addiction Medicine for the American Board of Preventive Medicine.  He is a member of the ASAM Publications Council and on the Editorial Board for the Journal of Addiction Medicine.

    Pathways to the Addiction Medicine Subspecialty Webinar Planning Committee 

    Name

    Disclosure

    Peter L. Selby MBBS, CCFP, FCFP, MHSc, DFASAM

    Johnson and Johnson: Consultant/Advisory Board, Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support;Pfizer: Consultant/Advisory Board, Other Research Support includes receipt of drugs, supplies, equipment

    Adam J. Gordon, MD, MPH, FACP, DFASAM

    No Financial Relationships or Conflicts of Interest

    Mark P. Schwartz, MD, FAAFP, DFASAMNo Financial Relationships or Conflicts of Interest
    Shawn Ryan, MD, MBA, FASAMAdapt & Braeburn:  Consultant
    Steven Daviss, MD, DFAPANo Financial Relationships or Conflicts of Interest
    Michael Weaver, MD, DFASAMNo Financial Relationships or Conflicts of Interest

    ASAM CME Committee 

    Name

    Disclosure

    Catherine Friedman, MD, FAPA, FASAM, Chair

    No Financial Relationships or Conflicts of Interest

    Adam J. Gordon, MD, MPH, FACP, DFASAM

    No Financial Relationships or Conflicts of Interest

    Noel Ilogu, MD, MRCP, DFASAM

    No Financial Relationships or Conflicts of Interest

    Herbert L. Malinoff, MD, FACP, DFASAM

    No Financial Relationships or Conflicts of Interest

    Edwin A. Salsitz, MD, DFASAM

    No Financial Relationships or Conflicts of Interest

    John C. Tanner, DO, DABAM, DFASAM, CCFC, MRO

    Indivior, Honorarium, Speaker; BDSI, Honorarium, Consultant/SpeakerCommercial Interest Definition


    A commercial interest is any entity producing, marketing, re-selling or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.

     

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Webinar: Improving the Language and Coverage of Addiction

    Contains 1 Component(s)

    In this webinar, ​in reflecting new scientific understanding of addiction, the speakers will offer guidance on how the media can accurately and fairly cover addiction through language, point-of-view, and style. The medical understanding of addiction and the science behind the disease has changed significantly. While the medical community changes the way it treats addiction, the media is also changing the way it covers addiction. The webinar will consider the stigma surrounding addiction and how the way the media covers the disease effects the public perception of the disease. Importantly, the webinar also will discuss the recent changes made to the AP Stylebook about the word “addict” and other stigmatizing words.​

    Addiction Treatment Week Logo

    In this webinar, in reflecting new scientific understanding of addiction, the speakers will offer guidance on how the media can accurately and fairly cover addiction through language, point-of-view, and style. The medical understanding of addiction and the science behind the disease has changed significantly. While the medical community changes the way it treats addiction, the media is also changing the way it covers addiction. The webinar will consider the stigma surrounding addiction and how the way the media covers the disease effects the public perception of the disease. Importantly, the webinar also will discuss the recent changes made to the AP Stylebook about the word “addict” and other stigmatizing words.

    Sarah Wakeman

    MD, FASAM

    Sarah E. Wakeman, MD is the Medical Director for the Mass General Hospital Substance Use Disorder Initiative, program director of the Mass General Addiction Medicine fellowship, and an Assistant Professor of Medicine at Harvard Medical School. She is also the Medical Director of the Mass General Hospital Addiction Consult Team, co-chair of the Mass General Opioid Task Force, and clinical lead of the Partners Healthcare Substance Use Disorder Initiative. She is the Medical Director of RIZE Massachusetts, a state-wide, private sector initiative created to build a $50 million fund to implement and evaluate innovative interventions to address the opioid overdose crisis. She received her A.B. from Brown University and her M.D. from Brown Medical School. She completed residency training in internal medicine and served as Chief Medical Resident at Mass General Hospital. She is a diplomate and fellow of the American Board of Addiction Medicine. She is chair of the policy committee for the Massachusetts Society of Addiction Medicine. She served on Massachusetts' Governor Baker’s Opioid Addiction Working Group. Nationally, she is chair of the American Society of Addiction Medicine Drug Court Task Force and serves on their ethics committee.Clinically she provides specialty addiction and general medical care in the inpatient and outpatient setting at Mass General Hospital and the Mass General Charlestown Health Center. Her research interests include evaluating models for integrated substance use disorder treatment in medical settings, recovery coaching, physician attitudes and practice related to substance use disorder, and screening for substance use in primary care.

    Michael P. Botticelli

    Executive Director of the Grayken Center for Addiction

    Michael Botticelli currently serves as the Executive Director of the Grayken Center for Addiction, Boston Medical Center.  Previously, Mr. Botticelli served as the Acting Director of National Drug Control Policy.  He also served as the Deputy Director of National Drug Control Policy, a position he held since 2012. Mr. Botticelli has more than two decades of experience supporting Americans who have been affected by substance use disorders. Prior to joining ONDCP, Mr. Botticelli served as Director of the Bureau of Substance Abuse Services at the Massachusetts Department of Public Health, where he successfully expanded innovative and nationally recognized prevention, intervention, treatment, and recovery services for the Commonwealth of Massachusetts. He also forged strong partnerships with local, state, and Federal law enforcement agencies; state and local health and human service agencies; and stakeholder groups to guide and implement evidence-based programs. These programs include the establishment of a treatment system for adolescents, early intervention and treatment programs in primary healthcare settings, jail diversion programs, re-entry services for those leaving correctional facilities, and overdose prevention programs. Mr. Botticelli has served in a variety of leadership roles for the National Association of State Alcohol and Drug Abuse Directors. He was also a member of the Advisory Committee for the Substance Abuse and Mental Health Services Administration's Center for Substance Abuse Prevention and the National Action Alliance for Suicide Prevention and has also co-authored many peer-reviewed articles that have significantly contributed to the field . In 2008, Mr. Botticelli was the first recipient of the annual Ramstad/Kennedy National Award for Outstanding Leadership in Promoting Addiction Recovery. In 2012, he was awarded the Service Award from the National Association of State Alcohol and Drug Abuse Directors. Born in Upstate New York, Mr. Botticelli holds a Bachelor of Arts from Siena College and a Master of Education from St. Lawrence University. He is also in long-term recovery from addiction, celebrating over 24 years of sobriety.

    Jeff McMillan

    Eastern US Enterprise Editor, the Associated Press

    Jeff McMillan is the East enterprise editor for The Associated Press, guiding investigations and features for one of the world’s largest newsgathering organizations in a region stretching from Ohio to Maine. He is an editor of the AP Stylebook, known as the “bible” for journalists on matters of usage and style, and was the primary author of its guidance on drugs and addiction. He is also the East region’s main consultant on journalistic standards. He is a graduate of the University of Minnesota.

    Addiction Medicine:  The Next Generation Webinar Planning Committee 

    Name

    Disclosure

    Peter L. Selby MBBS, CCFP, FCFP, MHSc, DFASAM, (Immediate Past Chair)

    Johnson and Johnson: Consultant/Advisory Board, Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support;Pfizer: Consultant/Advisory Board, Other Research Support includes receipt of drugs, supplies, equipment

    Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO, Chair

    No Financial Relationships or Conflicts of Interest

    Mark P. Schwartz, MD, FAAFP, DFASAMNo Financial Relationships or Conflicts of Interest
    Sarah E. Wakeman, MD, FASAMNo Financial Relationships or Conflicts of Interest
    Michael Botticelli, Director, Executive Director, Grayken Center for AddictionNo Financial Relationships or Conflicts of Interest
    Jeff McMillan, The Associated PressNo Financial Relationships or Conflicts of Interest

    ASAM CME Committee 

    Name

    Disclosure

    Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO, Chair

    No Financial Relationships or Conflicts of Interest

    Catherine Friedman, MD

    No Financial Relationships or Conflicts of Interest

    Noel Ilogu, MD, MRCP, DFASAM

    No Financial Relationships or Conflicts of Interest

    Herbert L. Malinoff, MD, FACP, DFASAM

    No Financial Relationships or Conflicts of Interest

    Edwin A. Salsitz, MD, DFASAM

    No Financial Relationships or Conflicts of Interest

    John C. Tanner, DO, DABAM, DFASAM, CCFC, MRO

    Indivior, Honorarium, Speaker; BDSI, Honorarium, Consultant/SpeakerCommercial Interest Definition


    A commercial interest is any entity producing, marketing, re-selling or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.